The company achieved Rule of 40 status with strong profitable growth. The share buyback and debt extension signal financial strength. Monitor 2026 execution against guidance as pricing uncertainty could create near-term headwinds.
Price Chart
Executive Summary
OptimizeRx reported strong 2025 financial results with record revenue of $109.4 million (up 19% YoY), GAAP net income of $5.1 million (vs. $20.1M loss), and adjusted EBITDA of $24.3 million (up 108% YoY). The company extended its debt maturity to 2029, authorized a $10 million share repurchase program, and maintained 2026 revenue guidance at $109-$114 million despite near-term headwinds from pricing uncertainty.
Key Financial Metrics
Key Facts
- Q4 revenue of $32.2M (flat YoY), full-year revenue of $109.4M (+19% YoY)
- GAAP net income of $5.1M in 2025 vs. $20.1M loss in 2024
- Adjusted EBITDA of $24.3M in 2025 (+108% YoY)
- Board authorized $10 million share repurchase program
- Debt maturity extended to October 2029
- 2026 revenue guidance maintained at $109-$114M
Financial Impact
Revenue up 19% to $109.4M, adjusted EBITDA up 108% to $24.3M, cash flow from operations up 282% to $18.7M
Risk Factors
- Near-term headwinds from uncertainty around Most Favored Nation pricing
- Customer caution on discretionary spending and contract duration
- Revenue concentration risk (52% from top 20 pharma manufacturers)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001448431-26-000002 |
| Document: oprx-20260305.htm | 0001448431-26-000002 |
| Document: 0001448431-26-000002-index-headers.html | 0001448431-26-000002 |
| Document: 0001448431-26-000002-index.html | 0001448431-26-000002 |
| Document: 0001448431-26-000002.txt | 0001448431-26-000002 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Press Release | $9.15 | awaiting T+20 | — | $9.07 (−0.87%) |
Oct 21, 2026 5d ago | SC 13G/A | $9.37 | awaiting T+20 | — | $9.07 (−3.20%) |
Sep 22, 2026 4w ago | Institutional Cluster | $7.62 $8.93 | ▲ +17.19% | ▲ +17.75% | $9.07 (+19.03%) |
Aug 12, 2026 10w ago | Press Release | $8.78 $7.29 | ▼ −16.97% | ▼ −15.22% | $9.07 (+3.30%) |
Jun 12, 2026 19w ago | 8-K | $5.32 $6.55 | ▲ +23.12% | ▲ +23.87% | $9.07 (+70.49%) |
Jun 11, 2026 19w ago | Institutional Cluster | $5.28 $6.28 | ▲ +18.94% | ▲ +17.05% | $9.07 (+71.78%) |
Jun 5, 2026 20w ago | 8-K | $5.05 $6.35 | ▲ +25.74% | ▲ +24.11% | $9.07 (+79.60%) |
Jun 1, 2026 21w ago | DEFA14A | $5.38 $5.72 | ▲ +6.32% | ▲ +7.62% | $9.07 (+68.59%) |
May 21, 2026 22w ago | Press Release | $4.94 $4.70 | ▼ −4.86% | ▼ −5.19% | $9.07 (+83.60%) |
May 12, 2026 23w ago | Press Release | $4.92 $5.28 | ▲ +7.32% | ▲ +7.93% | $9.07 (+84.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers